Saltar al contenido
Merck

C-053

Supelco

Carbamazepine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C15H12N2O
Número de CAS:
Peso molecular:
236.27
Número MDL:
Código UNSPSC:
41116107
NACRES:
NA.24
En este momento no podemos mostrarle ni los precios ni la disponibilidad

grado

certified reference material

Formulario

liquid

Características

SNAP-N-SPIKE®, SNAP-N-SHOOT®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

Clave InChI

FFGPTBGBLSHEPO-UHFFFAOYSA-N

Descripción general

Carbamazepine is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and neuropathic pain. Marketed under trade names including Carbatrol®, Tegretol®, Carbamaze, and Biston, carbamazepine is also used as a second line treatment for bipolar disorder and in conjunction with antipsychotic drugs for schizophrenia. Suitable uses of this Certified Spiking Solution® include as starting material for preparation of calibrators and controls in carbamazepine testing methods by GC/MS or LC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or therapeutic drug monitoring applications.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

Órganos de actuación

Eyes

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of

Artículos

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

Ver todo

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico